In the treatment of gastro-duodenal ulcers, a frequent kind of peptic ulcer, researchers from the pharmaceutical engineering and technology department at the Indian Institute of Technology-Banaras Hindu University (IIT-BHU) have made a major advancement.
Under the direction of research researcher Pankaj Paliwal and professor Sairam Krishnamurthy, the team created a new oral bioactive glass formulation with micronized barium oxide (BaBG), which has demonstrated promising therapeutic and preventive benefits against duodenal and stomach ulcers. This mixture neutralizes stomach acid, reducing the intensity of ulcers, and encourages cell division to facilitate healing. It also creates a barrier that keeps dangerous substances away from ulcers.
Prof Krishnamurthy highlighted that peptic ulcers affect 11.22% of India’s population, while duodenal ulcers have a global prevalence of 3%. These ulcers, more common in men, are often caused by H. pylori infection, non-steroidal anti-inflammatory drugs (NSAIDs), smoking, daily aspirin use, and gastrointestinal cancers. They occur when the stomach’s acidic defense is compromised, leading to ulcer formation.
Currently, Proton Pump Inhibitors (PPIs) and Histamine Type 2 Receptor Blockers are commonly used to reduce stomach acid and treat ulcers. However, long-term use of these medications can lead to side effects, underscoring the need for safer alternatives.
The safety and efficacy of this novel bioactive glass formulation have been extensively validated, with findings published in reputed journals such as Ceramics International and ACS Omega. BaBG’s longer half-life also ensures better patient compliance compared to current medications.
The research, titled “An Oral Bioactive Glass Formulation Containing Aqueous Micronized Barium Oxide for Treating Gastro-Duodenal Ulcers,” has been granted a patent by the Indian Patent Office. Doctoral students Pankaj Paliwal and Shreyasi Mujumdar played pivotal roles in the research, which spans over a decade. According to Professor Krishnamurthy, the product is expected to enter the market following successful clinical trials.
Get the latest news updates and stay informed with FELA NEWS!
Source: HT
